Sunday 11 October 2026
Export all MRK data to Excel Powerpack
Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
145.60
3.22
+2.26%
Follow MRK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 6.97% | 18.94% | 36.86% | 39.46% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 4 | 4 | 6 | |
| 2.57% | 7.33% | 14.37% | 15.41% | ||
ROIC |
5.08% | 9.33% | 16.28% | 19.00% | |
Return on Tangible Assets |
9.15% | 26.67% | 45.07% | 42.71% | |
Average Days of Receivables |
68.89 | 67.76 | 66.11 | 68.87 | |
Free Cash Flow per Share |
6.50 | 5.71 | 4.94 | 5.23 | |
Free Cash Flow |
16,063.00 | 14,115.00 | 12,360.00 | 13,049.00 | |
Capital Expenditures |
(3,904.00) | (3,775.00) | (4,112.00) | (4,016.00) | |
| Other line items | |||||
Cash ROIC |
16.03% | 14.36% | 10.84% | 11.85% | |
Accounts Receivable Turnover |
5.45 | 5.72 | 5.90 | 5.47 | |
Accounts Payable Turnover |
4.66 | 4.49 | 3.86 | 3.79 | |
Inventory Turnover |
2.81 | 2.71 | 2.57 | 2.31 | |
Average Days of Payables |
77.62 | 82.18 | 98.12 | 103.26 | |
Days of Inventory on Hand |
125.89 | 137.83 | 148.34 | 160.45 | |
Tax Rate |
(0.47) | (0.23) | (0.13) | (0.13) | |
Research and Development Expense of Revenue |
45.75% | 37.65% | 24.29% | 25.67% | |
Selling, General and Administrative Expense of Revenue |
16.73% | 16.54% | 16.51% | 16.65% | |
Share Based Compensation of Revenue |
1.34% | 1.23% | 1.26% | 1.25% | |
Operating CF/Net income |
6.29 | 2.00 | 0.90 | 0.90 | |
Depreciation/Fixed assets |
0.26 | 0.25 | 0.23 | 0.18 | |
Capex/Depreciation |
(0.58) | (0.60) | (0.70) | (0.88) | |
Revenue per Share |
26.95 | 26.61 | 25.98 | 25.75 | |
Operating CF per Share |
8.08 | 7.24 | 6.58 | 6.84 | |
Capex per Share |
(1.58) | (1.53) | (1.64) | (1.61) | |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.06 |
Columns are period end dates